PPARγ ligands and their therapeutic applications: a patent review (2008 – 2014)

Bibliography

• Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 2005;97:177-83
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20:1405-28
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312
   PubMed Web of Science ®Google Scholar
• Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 2013;19:557-66
   PubMed Web of Science ®Google Scholar
• He W. PPARγ2 polymorphism and human health. PPAR Res 2009;2009:849538
   PubMedGoogle Scholar
• Takada I, Kouzmenko AP, Kato S. PPAR-gamma signaling crosstalk in mesenchymal stem cells. PPAR Res 2010;doi:10.1155/2010/341671
   Google Scholar
• Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-63
   PubMed Web of Science ®Google Scholar
• Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15
   PubMed Web of Science ®Google Scholar
• Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-6
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Mitka M. FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA 2013;310:2604
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• FDA requires removal of certain restrictions on the diabetes drug Avandia. FDA News Release. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm [Last accessed 25 November 2013]
   Google Scholar
• European Medicines Agency. Assesment report for Avandia. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000268/WC500029109.pdf [Last accessed 17 January 2011]
   Google Scholar
• Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803-41
   PubMed Web of Science ®Google Scholar
• Galderma Researh & Development. Novel biaromatic compounds that modulate PPAR-receptors. US0012129; 2009
   Google Scholar
• Galderma Research & Development. Novel 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof. US0144884; 2010
   Google Scholar
• Schmuth M, Jiang YJ, Dubrac S, et al. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008;49:499-509
   PubMed Web of Science ®Google Scholar
• The University of Tokyo. α-Substituted phenylpropionic acid derivatives. WO004341; 2008
   Google Scholar
• Miyachi H, Nomura M, Tanase T, et al. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators. Bioorg Med Chem Lett 2002;12:77-80
   PubMed Web of Science ®Google Scholar
• Kasuga J, Yamasaki D, Ogura K, et al. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. Bioorg Med Chem Lett 2008;18:1110-15
   Google Scholar
• Raval P, Jain M, Goswami A, et al. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. Bioorg Med Chem Lett 2011;21:3103-9
   PubMed Web of Science ®Google Scholar
• Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same. WO108602; 2008
   Google Scholar
• Kim MK, Chae YN, Kim HS, et al. PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Arch Pharm Res 2009;32:721-7
   PubMed Web of Science ®Google Scholar
• Okayama University. Novel α-substituted propionic derivatives. JP2012041334; 2010
   Google Scholar
• Ohashi M, Nakagome I, Kasuga J, et al. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry-activity relationship. Bioorg Med Chem 2012;20:6375-83
   Google Scholar
• Sauerberg P, Pettersson I, Jeppesen L, et al. Novel Tricyclic-α-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 2002;45:789-804
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity. WO137105; 2008
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Fused ring compounds as partial agonists of PPAR-gamma. WO099794; 2008
   Google Scholar
• Merck & Co., Inc. Novel crystalline salt form of an antidiabetic compound. WO109334; 2008
   Google Scholar
• Merck & Co., Inc. Fused aromatic compounds having anti-diabetic activity. WO096564; 2006
   Google Scholar
• Acton JJIII, Akiyama TE, Chang CH, et al. Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1 -yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 2009;52:3846-54
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co., Ltd. Crystalline forms of thiazolidinedione compound and its manufacturing method. US0160462; 2011
   Google Scholar
• Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006;25:2304-17
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012;118:5403-13
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab 2013;98:2392-400
   PubMed Web of Science ®Google Scholar
• Lee SY, Hur GY, Jung KH, et al. PPAR-gamma agonist increase gefitinib’s antitumor activity through PTEN expression. Lung Cancer 2006;51:297-301
   Google Scholar
• Oton AB, Cho BC, Ahn M-J, et al. A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC). American Association for Cancer Research Annual Meeting; 2014. Available from: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=8#.VErgpUvFTNo
   Google Scholar
• Serizawa M, Murakami H, Watanabe M, et al. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells. Cancer Sci 2014;105:683-9
   PubMed Web of Science ®Google Scholar
• Vivacell Biotechnology España, S.L. Cannabinoid quinone derivatives. WO117429; 2011
   Google Scholar
• Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009;5:442-7
   PubMed Web of Science ®Google Scholar
• Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010;466:451-6
   PubMed Web of Science ®Google Scholar
• Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477:477-81
   PubMed Web of Science ®Google Scholar
• Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders. WO091134; 2011
   Google Scholar
• Metabolic Solutions Development Co., LLC. Novel synthesis for thiazolidinedione compounds. WO021476; 2012
   Google Scholar
• Metabolic Solutions Development Co., LLC. Synthesis for thiazolidinedione compounds. WO021467; 2012
   Google Scholar
• The University of Sydney. PPAR agonists. WO026658; 2009
   Google Scholar
• The University of Sydney. Flavnoid PPAR agonists. WO021467; 2009
   Google Scholar
• Salam NK, Huang TH, Kota BP, et al. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 2008;71:57-70
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use. US0022603; 2010
   Google Scholar
• Keil S, Matter H, Schonafinger K, et al. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy. ChemMedChem 2011;6:633-53
   PubMedGoogle Scholar
• Kindex Therapeutics, LLC. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods. WO058649; 2012
   Google Scholar
• Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012;483:350-4
   PubMed Web of Science ®Google Scholar
• Konda VR, Desai A, Darland G, et al. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PLoS One 2014;9:e87848
   PubMed Web of Science ®Google Scholar
• Koren N, Simsa-Maziel S, Shahar R, et al. Exposure to omega-3 fatty acids at early age accelerate bone growth and improve bone quality. J Nutr Biochem 2014;25:623-33
   PubMed Web of Science ®Google Scholar
• Kowa Co., Ltd. Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-one structure and drugs that comprise same. WO095462; 2010
   Google Scholar
• Kowa Co., Ltd. Novel 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative and pharmaceutical product containing same. WO077712; 2011
   Google Scholar
• Kowa Co., Ltd. Novel phenylpyridine derivative and drug containing same. WO124311; 2012
   Google Scholar
• Kowa Co., Ltd. Novel 2-pyridone derivative and pharmaceutical product containing same. WO077711; 2011
   Google Scholar
• The Regents of the University of California. Inhibition of PPAR gamma expression in preadipocyte cells by oxysterols. WO006087; 2011
   Google Scholar
• Kim WK, Meliton V, Amantea CM, et al. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. J Bone Miner Res 2007;22:1711-19
   Google Scholar
• ProMD Biotech Co., Ltd. Method for enhancing PPARγ expression. US20130344043; 2013
   Google Scholar
• Okuno A, Yoshia T, Ogawa J. Pharmaceutical composition containing PPARgamma agonist. US20090137626; 2009
   Google Scholar
• Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011;48:885-93
   PubMed Web of Science ®Google Scholar
• Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011;112:2902-9
   PubMed Web of Science ®Google Scholar
• Wellstat Therapeutics Corp. Combination treatment of metabolic disorders. WO117791; 2007
   Google Scholar
• InteKrin Therapeutics, Inc. Combination of PPARγ agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity. WO111078; 2009
   Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Kyle KA, Willett TL, Baggio LL, et al. Differential effects of PPAR-gamma activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011;152:457-67
   PubMed Web of Science ®Google Scholar
• Lanfear D, Higgins L. Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity. US0034380; 2011
   Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-46
   PubMed Web of Science ®Google Scholar
• da Rocha Junior LF, Dantas AT, Duarte AL, et al. PPARγ agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res 2013;2013:519724
   PubMed Web of Science ®Google Scholar
• Cipolletta D, Feuerer M, Li A, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012;486:549-53
   PubMed Web of Science ®Google Scholar
• Klotz L, Burgdorf S, Dani I, et al. The nuclear receptor PPARgamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009;206:2079-89
   PubMed Web of Science ®Google Scholar
• Giuliani International Ltd. PPAR-gamma agonists for the induction of ationic antimicrobial peptide expression as immunoprotective stimulants. WO104557; 2008
   Google Scholar
• Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009;31:368-76
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor γ activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010;107:8772-7
   PubMed Web of Science ®Google Scholar
• La Jolla Institute for Allergy and Immunology. Regulatory T cells and methods of making and using same. WO157394; 2008
   Google Scholar
• Wohlfert EA, Nichols FC, Nevius E, et al. Peroxisome proliferator-activated receptor (PPAR) and immunoregulation: enhancement of regulatory T cells through PPAR -dependent and -independent mechanisms. J Immunol 2007;178:4129-35
   PubMed Web of Science ®Google Scholar
• Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat and prevent diseases and disorders. US0216883; 2010
   Google Scholar
• Guri AJ, Evans NP, Hontecillas R, et al. T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem 2011;22:812-19
   PubMed Web of Science ®Google Scholar
• Rheinische Friedrich-Wilhelms Universität. PPAR gamma agonists for treating illnesses with pathophysiological participation of TH17 lymphocytes. EP2301539; 2011
   Google Scholar
• Cardoz AB. Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a PPAR gamma agonist. WO007673; 2009
   Google Scholar
• VanderLaan PA, Reardon CA. The immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res 2005;46:829-38
   PubMed Web of Science ®Google Scholar
• Pulmagen Therapeutics (Inflammation) Ltd. Sulfonamide compounds for the treatment of respiratory disorders. WO076553; 2010
   Google Scholar
• Pulmagen Therapeutics (Inflammation) Ltd. Inflammatory disease treatment. WO098801; 2011
   Google Scholar
• Inhalated PPAR gamma agonists. Pulmagen Therapeutics. Burnham, Bucks, UK. Available from: http://www.pulmagen.com/ppary.html
   Google Scholar
• InteKrin Therapeutics, Inc. PPARγ agonists for treatment of multiple sclerosis. WO120538; 2014
   Google Scholar
• Lee DH, Huang H, Choi K, et al. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab 2012;302:E552-E60
   PubMed Web of Science ®Google Scholar
• Higgins LS, Mantzoros CS. The Development of INT131 as a selective PPARγ modulator: approach to a safer insulin sensitizer. PPAR Res 2008;2008:936906
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham. PPAR-gamma agonists for improvement of cognitive function in Apoe4 negative patients. US0262047; 2008
   Google Scholar
• Poirier J, Miron J, Picard C, et al. Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer’s disease. Neurobiol Aging 2014;35S2:S3-S10
   Google Scholar
• Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013;108:21-43
   PubMed Web of Science ®Google Scholar
• Brodbeck J, Balestra ME, Saunders AM, et al. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci USA 2008;105:1343-6
   PubMed Web of Science ®Google Scholar
• Omeros Corp. Compositions and methods for prophylaxis and treatment of addictions. EP2612553; 2013
   Google Scholar
• Omeros Corp. Compositions and methods for prophylaxis and treatment of addictions. WO105103; 2010
   Google Scholar
• Stopponi S, Somaini L, Cippitelli A, et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011;69:642-9
   PubMed Web of Science ®Google Scholar
• Aestus Therapeutics, Inc. Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma. US0024692; 2014
   Google Scholar
• Fujimura T, Sakuma H, Konishi S, et al. FK614, a novel peroxisome proliferator-activated receptor γ modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 2005;99:342-52
   PubMed Web of Science ®Google Scholar
• Aestus Therapuetics and Astellas Pharma signs license deal for novel chronic pain therapeutic. Business Wire. Available from: http://www.businesswire.com/news/home/20100628005490/en/Aestus-Therapeutics-Astellas-Pharma-Sign-License-Deal [Last accessed 28 June 2008]
   Google Scholar
• Aestus Theraoeytucs, Inc. Methods of treating neuropathic pain with agonists of PPAR-gamma. WO063842; 2008
   Google Scholar
• Churi SB, Abdel-Aleem OS, Tumber KK, et al. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49
   PubMed Web of Science ®Google Scholar
• Maeda T, Kiguchi N, Kobayashi Y, et al. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7
   PubMed Web of Science ®Google Scholar
• Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007;320:1002-12
   PubMed Web of Science ®Google Scholar
• Aestus therapeutics reports positive results in phase II neuropathic pain trial for treatment of post-herpetic neuralgia. Business Wire. Available from: http://www.businesswire.com/news/home/20111213005815/en/Aestus-Therapeutics-Reports-Positive-Results-Phase-II [Last accessed 13 December 2011]
   Google Scholar
• Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000;136:609-16
   PubMed Web of Science ®Google Scholar
• Umbert Millet I. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same. WO153373; 2009
   Google Scholar
• Avon Products, Inc. Use of eclipta prostrata and other PPAR-gamma inhibitors in cosmetics and compositions thereof. WO156136; 2011
   Google Scholar
• Pusan National University Indusrty University. Novel compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor. WO108677; 2012
   Google Scholar
• Wiechers JW, Rawlings AV, Garcia C, et al. A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor. Int J Cosmet Sci 2005;27:123-32
   Google Scholar
• Park MH, Park JY, Lee HJ, et al. The novel PPARα/γ dual agonist MHY 966 modulates UVB-induced skin inflammation by inhibiting NF-κB activity. PLoS One 2013;8:e76820
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Composition comprising peroxisome proliferator-activated receptor-gamma (PPAR). WO117013; 2012
   Google Scholar
• Cedars-Sinai Medical Center. Methods of using PPAR-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer. WO008767; 2008
   Google Scholar
• Akasaki Y, Liu G, Matundan HH, et al. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006;281:6165-74
   PubMed Web of Science ®Google Scholar
• Wang L, Yu CJ, Liu W, et al. Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin 2011;32:991-8
   PubMed Web of Science ®Google Scholar
• Centre National de la Recherche Scientifique. RXR-PPARgamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer. WO070379; 2010
   Google Scholar
• Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:604-15
   PubMed Web of Science ®Google Scholar
• Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. Cell 2014;157:255-66
   PubMed Web of Science ®Google Scholar
• Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of adverse effect due to the use of PPAR-gamma agonists. WO141897; 2008
   Google Scholar
• Patano N, Mancini L, Settanni MP, et al. l-Carnitine fumarate and isovaleryl-l-carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimetally induced osteoporosis in pregnant mice. Calcif Tissue Int 2008;82:221-8
   PubMed Web of Science ®Google Scholar
• Santen Pharmaceutical Co., Ltd. Agent for enhancing corneal epithelial barrier function. WO107652; 2009
   Google Scholar
• Indiana University Research and Technology Corp. Use of PPAR gamma modulators to treat cystic liver diseases. WO028370; 2010
   Google Scholar
• Nagao S, Yamaguchi T. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 2012;5:292-300
   Google Scholar
• Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol 2014;143C:207-22
   Google Scholar
• Zhang X, Lanter JC, Sui Z. Recent advances in the development of selective androgen receptor modulators. Expert Opin Ther Pat 2009;19:1239-58
   PubMed Web of Science ®Google Scholar
• Yamada S, Makishima M. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators. Trends Pharmacol Sci 2014;35:324-37
   PubMed Web of Science ®Google Scholar
• Choi M, Makishima M. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin Ther Pat 2009;19:593-606
   PubMed Web of Science ®Google Scholar
• Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance. FDA Guidance for Industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf [Last accessed 3 March 2008]
   Google Scholar
• Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311:1515-25
   PubMed Web of Science ®Google Scholar